These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 21570499)

  • 1. Proteomics and biomarkers in clinical trials for drug development.
    Lee JM; Han JJ; Altwerger G; Kohn EC
    J Proteomics; 2011 Nov; 74(12):2632-41. PubMed ID: 21570499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies in functional proteomics: Unveiling the pathways to precision oncology.
    Favicchio R; Thepaut C; Zhang H; Arends R; Stebbing J; Giamas G
    Cancer Lett; 2016 Nov; 382(1):86-94. PubMed ID: 26850375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomics as a guiding tool for more effective personalized therapy.
    Lee JM; Kohn EC
    Ann Oncol; 2010 Oct; 21 Suppl 7(Suppl 7):vii205-10. PubMed ID: 20943616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications.
    Jimenez CR; Verheul HM
    Am Soc Clin Oncol Educ Book; 2014; ():e504-10. PubMed ID: 24857147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reverse phase protein microarrays advance to use in clinical trials.
    Mueller C; Liotta LA; Espina V
    Mol Oncol; 2010 Dec; 4(6):461-81. PubMed ID: 20974554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.
    Ang JE; Kaye S; Banerji U
    Curr Drug Targets; 2012 Nov; 13(12):1525-34. PubMed ID: 22974395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomics and ovarian cancer: integrating proteomics information into clinical care.
    Hays JL; Kim G; Giuroiu I; Kohn EC
    J Proteomics; 2010 Sep; 73(10):1864-72. PubMed ID: 20561909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic Approaches for Biomarker Panels in Cancer.
    Tanase C; Albulescu R; Neagu M
    J Immunoassay Immunochem; 2016; 37(1):1-15. PubMed ID: 26565430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma membrane proteomics and its application in clinical cancer biomarker discovery.
    Leth-Larsen R; Lund RR; Ditzel HJ
    Mol Cell Proteomics; 2010 Jul; 9(7):1369-82. PubMed ID: 20382631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
    Lin F; Li Z; Hua Y; Lim YP
    Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized molecular medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients.
    Murph MM; Smith DL; Hennessy B; Lu Y; Joy C; Coombes KR; Mills GB
    Adv Exp Med Biol; 2008; 622():183-95. PubMed ID: 18546628
    [No Abstract]   [Full Text] [Related]  

  • 14. Emerging applications for phospho-proteomics in cancer molecular therapeutics.
    Moran MF; Tong J; Taylor P; Ewing RM
    Biochim Biophys Acta; 2006 Dec; 1766(2):230-41. PubMed ID: 16889898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of new proteomics strategies for biology and medicine.
    Domon B; Broder S
    J Proteome Res; 2004; 3(2):253-60. PubMed ID: 15113101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.
    Wang J; Mouradov D; Wang X; Jorissen RN; Chambers MC; Zimmerman LJ; Vasaikar S; Love CG; Li S; Lowes K; Leuchowius KJ; Jousset H; Weinstock J; Yau C; Mariadason J; Shi Z; Ban Y; Chen X; Coffey RJC; Slebos RJC; Burgess AW; Liebler DC; Zhang B; Sieber OM
    Gastroenterology; 2017 Oct; 153(4):1082-1095. PubMed ID: 28625833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.
    Ryu J; Thomas SN
    Molecules; 2021 May; 26(9):. PubMed ID: 34063568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics of ovarian cancer: functional insights and clinical applications.
    Elzek MA; Rodland KD
    Cancer Metastasis Rev; 2015 Mar; 34(1):83-96. PubMed ID: 25736266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular insights into cancer drug resistance from a proteomics perspective.
    An Y; Zhou L; Huang Z; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2019 May; 16(5):413-429. PubMed ID: 30925852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.